A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease

Autor: William J. Sandborn, Subrata Ghosh, Julian Panes, Ivana Vranic, Wenjin Wang, Wojciech Niezychowski, Severine A.R.A. Vermeire, Olivier Dewit, Harald Peeters, Jiri Stehlik, Tomas Vanasek, David Laharie, Jean Frederic Colombel, Marc-André Bigard, Marta Varga, Margit Zeher, Janos Novak, Bela Hunyady, Agnes Salamon, Istvan Racz, Paolo Gionchetti, Anna Kohn, Cosimo Prantera, P.C.F. Stokkers, Maria Slomka, Leszek Paradowski, Tomasz Arlukowicz, Ladislav Kuzela, Boris Baricky, Tibor Hlavaty, Maria Isabel Vera, Jordi Guardiola, Christopher Probert, Jonathan Lionel Shaffer, Mark Fleisher, Ronald Edward Pruitt, John Sawyer Goff, John Weber, Raymond Lloyd Bell, Andrew Harrison Zwick, Alexandra Gutierrez, Robert H. Levine, Stephen Brett Hanauer, Lori Ann Lavelle, Ravindranath K. Kottoor, Gerald Wayne Dryden, Robert Hardi, David Vaughn Glorioso, Prabhakar Swaroop, Scott D. Lee, Teressa Joan Patrick, Sheldon Scheinert, Charles A. Sninsky, Seymour Katz, Mark D. Noar, Michael Marion Gaspari, Glenn L. Gordon, Thomas A. Dalton, Douglas Edward Homoky, William Ransom Kilgore, Joel A. Levien, Herbert R. Schneider, Suleman Abdul Moola, Frederik Cornelius Kruger, John P. Wright, Nazimuddin Aboo

Publikováno v: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 12(9)

BACKGROUND & AIMS: Tofacitinib, an orally administered Janus kinase inhibitor, blocks signaling through γ-chain-containing cytokines (interleukins 2, 4, 7, 9, 15, and 21). We performed a phase 2 trial to measure its efficacy in patients with moderat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6051c427211b36e8b77a28bed0db68df
https://pubmed.ncbi.nlm.nih.gov/24480677